These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8422901

  • 1. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion.
    Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J.
    Eur J Pharmacol; 1993 Jan 12; 230(2):195-201. PubMed ID: 8422901
    [Abstract] [Full Text] [Related]

  • 2. In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783.
    Vaugeois JM, Bonnet JJ, Costentin J.
    Eur J Pharmacol; 1992 Jan 07; 210(1):77-84. PubMed ID: 1350989
    [Abstract] [Full Text] [Related]

  • 3. Quantitative autoradiography of the dopamine uptake complex in rat brain using [3H]GBR 12935: binding characteristics.
    Richfield EK.
    Brain Res; 1991 Feb 01; 540(1-2):1-13. PubMed ID: 1829013
    [Abstract] [Full Text] [Related]

  • 4. Relationship between the effects of dexamphetamine on locomotion and on striatal [3H]GBR 12783 binding in vivo.
    Vaugeois JM, Bonnet JJ, Costentin J.
    Eur J Pharmacol; 1990 Mar 20; 178(2):221-7. PubMed ID: 2328762
    [Abstract] [Full Text] [Related]

  • 5. Endogenous dopamine differently affects N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine and cocaine binding to the dopamine uptake complex.
    Maurice T, Barbanel G, Vignon J.
    Gen Pharmacol; 1993 Jan 20; 24(1):191-4. PubMed ID: 8482495
    [Abstract] [Full Text] [Related]

  • 6. Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter.
    Rothman RB, Grieg N, Kim A, De Costa BR, Rice KC, Carroll FI, Pert A.
    Pharmacol Biochem Behav; 1992 Dec 20; 43(4):1135-42. PubMed ID: 1475296
    [Abstract] [Full Text] [Related]

  • 7. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
    Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W.
    Arch Biochem Biophys; 1990 Feb 01; 276(2):424-32. PubMed ID: 2306106
    [Abstract] [Full Text] [Related]

  • 8. Modulation by dopamine of [3H]N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine ([3H]BTCP, a phencyclidine derivative) binding to the dopamine uptake complex.
    Maurice T, Barbanel G, Kamenka JM, Vignon J.
    Neuropharmacology; 1991 Jun 01; 30(6):591-8. PubMed ID: 1681444
    [Abstract] [Full Text] [Related]

  • 9. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers.
    Xu C, Coffey LL, Reith ME.
    Biochem Pharmacol; 1995 Jan 31; 49(3):339-50. PubMed ID: 7857321
    [Abstract] [Full Text] [Related]

  • 10. Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs.
    Desai RI, Kopajtic TA, French D, Newman AH, Katz JL.
    J Pharmacol Exp Ther; 2005 Oct 31; 315(1):397-404. PubMed ID: 16014753
    [Abstract] [Full Text] [Related]

  • 11. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier.
    Héron C, Costentin J, Bonnet JJ.
    Eur J Pharmacol; 1994 Nov 03; 264(3):391-8. PubMed ID: 7698180
    [Abstract] [Full Text] [Related]

  • 12. Interaction of two sulfhydryl reagents with a cation recognition site on the neuronal dopamine carrier evidences small differences between [3H]GBR 12783 and [3H]cocaine binding sites.
    Refahi-Lyamani F, Saadouni S, Costentin J, Bonnet JJ.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Feb 03; 351(2):136-45. PubMed ID: 7770096
    [Abstract] [Full Text] [Related]

  • 13. High-affinity [3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system.
    Bonnet JJ, Protais P, Chagraoui A, Costentin J.
    Eur J Pharmacol; 1986 Jul 31; 126(3):211-22. PubMed ID: 3489625
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).
    Matecka D, Rothman RB, Radesca L, de Costa BR, Dersch CM, Partilla JS, Pert A, Glowa JR, Wojnicki FH, Rice KC.
    J Med Chem; 1996 Nov 22; 39(24):4704-16. PubMed ID: 8941383
    [Abstract] [Full Text] [Related]

  • 17. Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier.
    Saadouni S, Refahi-Lyamani F, Costentin J, Bonnet JJ.
    Eur J Pharmacol; 1994 Jul 15; 268(2):187-97. PubMed ID: 7957640
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.
    Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB.
    Ann N Y Acad Sci; 2002 Jun 15; 965():92-108. PubMed ID: 12105088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.